Statistiche di base
| LEI | 529900Y6YUB5X93MMD77 |
| CIK | 1041024 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rockwell Medical, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 14, 2025 |
Performance Based Restricted Stock Unit Award Agreement. Exhibit 10.2 Grantee: Grant Date: Total Number of Performance-Based Restricted Stock Units: PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT THIS PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”), dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and the individual set |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2025 |
Rockwell Medical, Inc. Amended and Restated Exhibit 10.1 ROCKWELL MEDICAL, INC. AMENDED AND RESTATED 2018 LONG TERM INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On April 13, 2018, the Board initially adopted the Rockwell Medical, Inc. 2018 Long Term Incentive Plan, subject to the approval of shareholders at the Corporation's 2018 annual meeting of shareholders. The plan was first amended and restated effective May 18, 2020, furth |
|
| August 14, 2025 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| August 14, 2025 |
Rockwell Medical Announces Second Quarter 2025 Results Rockwell Medical Announces Second Quarter 2025 Results •Generated $1.8 million in cash flow from operations for the second quarter of 2025. •Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. •Increased cash position at June 30, 2025 to $18.4 million. Wixom, Michigan, August 14, 2025 – Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company |
|
| August 14, 2025 |
Calculation of Filing Fee Table. Calculation of Filing Fee Tables S-8 ROCKWELL MEDICAL, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.0001 per share 457(a) 5,000,000 $ 1.00 $ 5,000,000.00 0.0001531 $ 765.50 Total Offe |
|
| August 14, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 Registration No. |
|
| May 20, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 12, 2025 |
Rockwell Medical Announces First Quarter 2025 Results Exhibit 99.1 Rockwell Medical Announces First Quarter 2025 Results · Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. · Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Wixom, Michigan, May 12, 2025 – Rockwell Medical, Inc. (the "Company") (Nasdaq: |
|
| May 12, 2025 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 12, 2025 |
Rockwell Medical, Inc. Corporate Presentation, dated May 12, 2025 a20250512rmtiinvestorpre |
|
| April 14, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 20, 2025 |
Rockwell Medical, Inc. Corporate Presentation, dated March 20, 2025 |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-236 |
|
| March 20, 2025 |
Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results Exhibit 99.1 Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results · Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. · Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. · Reports record net sales for the third year in a row |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| December 12, 2024 |
Employment Agreement, dated as of October 16, 2023, between the Company and Jesse Neri. Exhibit 10.1 Employment Agreement This Employment Agreement (the “Agreement”) is made as of October 16, 2023 (the “Effective Date”), by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and Jesse Neri (“Executive”), subject to the terms and conditions defined in this Agreement. WHEREAS, the Company and Executive desire the Executive be employed by the Company to act as th |
|
| November 14, 2024 |
RMTI / Rockwell Medical, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-rmti093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ROCKWELL MEDICAL, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 774374300 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 13, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2024 |
ROCKWELL MEDICAL, INC. Up to $25,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-282538 PROSPECTUS SUPPLEMENT (To Prospectus dated October 21, 2024) ROCKWELL MEDICAL, INC. Up to $25,000,000 Common Stock We have previously entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, no par value |
|
| November 12, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKW |
|
| November 12, 2024 |
Rockwell Medical, Inc. Corporate Presentation, dated November 12, 2024 |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2024 |
Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter •Reports net product sales of $28. |
|
| October 17, 2024 |
ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 October 17, 2024 VIA EDGAR Joshua Gorsky Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Re: Rockwell Medical, Inc. Registration Statement on Form S-3 File No. 333-282538 Dear Mr. Gorsky: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| October 17, 2024 |
ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 October 17, 2024 VIA EDGAR Joshua Gorsky Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Re: Rockwell Medical, Inc. Registration Statement on Form S-3 File No. 333-282538 Dear Mr. Gorsky: Pursuant to Rule 461 under the Securities Act of 1933, as amended |
|
| October 8, 2024 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Rockwell Medical, Inc. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 8, 2024. |
|
| October 8, 2024 |
As filed with the Securities and Exchange Commission on October 8, 2024 Registration No. |
|
| October 8, 2024 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Rockwell Medical, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| August 8, 2024 |
Rockwell Medical, Inc. Corporate Presentation, dated August 8, 2024 |
|
| August 8, 2024 |
Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024 •Reports net sales of $25. |
|
| August 8, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| August 8, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 15, 2024 |
Exhibit 10.1 Amendment No. 1 to Asset Purchase Agreement This Amendment No. 1 to Asset Purchase Agreement (this “Amendment”) is made as of July 12, 2024, by and between Evoqua Water Technologies LLC, a Delaware limited liability company (“Seller”), and Rockwell Medical, Inc., a Delaware corporation (“Purchaser” and together with Seller, the “Parties”). Capitalized terms used and not otherwise defi |
|
| May 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2024 |
Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance •Reports record net sales of $22. |
|
| May 14, 2024 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 14, 2024 |
Rockwell Medical, Inc. Corporate Presentation, dated May 14, 2024 |
|
| May 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| March 21, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-236 |
|
| March 21, 2024 |
Exhibit 99.1 Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023 · Reports record net sales for second year in a row, generating $83.6 million in 2023, an increase of 15% over 2022. Net sales for the fourth quarter of 2023 were $22.1 million, an increase of 14% over the same period |
|
| March 21, 2024 |
(Exhibit 10.31 to the Company's Form 10-K filed on March 21, 2024). Exhibit 10.31 ROCKWELL MEDICAL, INC. AMENDED AND RESTATED CLAWBACK POLICY (THE “POLICY”) Recoupment of Incentive-Based Compensation It is the policy of Rockwell Medical, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal s |
|
| March 21, 2024 |
Rockwell Medical, Inc. Corporate Presentation, dated March 21, 2024 |
|
| March 21, 2024 |
Rockwell Medical, Inc. Statement of Company Policy Prohibiting Insider Trading Exhibit 10.32 ROCKWELL MEDICAL, INC. AMENDED AND RESTATED STATEMENT OF COMPANY POLICY PROHIBITING INSIDER TRADING Because the common stock of Rockwell Medical, Inc. (the “Company”) is publicly traded on the NASDAQ, there are certain important restrictions and limitations imposed on you under the federal securities laws. Any violation of these restrictions may subject the Company and you to serious |
|
| March 21, 2024 |
Employment Agreement dated July 21, 2021 between Rockwell Medical, Inc. and Megan Timmins. Exhibit 10.30 Employment Agreement This Employment Agreement (the “Agreement”) is made as of July 21, 2021 (the “Effective Date”), by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and Megan C. Timmins (“Executive”), subject to the terms and conditions defined in this Agreement. WHEREAS, the Company and Executive desire the Executive be employed by the Company to act a |
|
| February 14, 2024 |
US7743743004 / Rockwell Medical Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2024 |
Rockwell Medical, Inc. Corporate Presentation, dated January 8, 2024 a20240108rmtiinvestorpre |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED (I) UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR (II) WITHOUT AN OPINION OF COUNSEL, IN FORM |
|
| January 8, 2024 |
Exhibit 99.1 Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enhances the Company's cash balance Rockwell Medical provides preliminary projected fourth quarter and full-year 2023 financial results Wixom, Michigan, January 8, 2024 – |
|
| January 8, 2024 |
Exhibit 10.1 THIRD AMENDMENT TO AND RESTATEMENT OF LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO AND RESTATEMENT OF LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”), dated as of January 1, 2024 (the “Effective Date”), among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as coll |
|
| November 14, 2023 |
Rockwell Medical Announces Third Quarter 2023 Results Exhibit 99.1 Rockwell Medical Announces Third Quarter 2023 Results · Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. · Gross profit for the third quarter of 2023 increased 183% over the same period in 2022. Gross margin for the third quarter of 2023 was 9%, an |
|
| November 14, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKW |
|
| November 14, 2023 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 14, 2023 |
Rockwell Medical, Inc. Corporate Presentation, dated November 14, 2023 |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| September 21, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissi |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissi |
|
| September 12, 2023 |
a20230912rmtiinvestorpre Investor Presentation September 12, 2023 Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2023 guidance, potential EBITDA margin from the Evoqua Water Technologies transaction, future net sales, reliance on capital investments, ability to grow, industry leadership position, and maintain concentrate sales. |
|
| September 12, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissi |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 17)1 Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value 0.0001 per share (Title of Class of Securities) 774374102 (CUSIP Number) DAVID S. RICH |
|
| August 21, 2023 |
ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 ROCKWELL MEDICAL, INC. 30142 S. Wixom Road Wixom, MI 48393 August 21, 2023 VIA EDGAR Jimmy McNamara Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549-3561 Re: Rockwell Medical, Inc. Registration Statement on Form S-3 File No. 333-273983 Dear Mr. McNamara: Pursuant to Rule 461 under the Securities Act of 1933, as amend |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 14, 2023 Registration No. |
|
| August 15, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Rockwell Medical, Inc. |
|
| August 15, 2023 |
As filed with the Securities and Exchange Commission on August 14, 2023 Registration No. |
|
| August 15, 2023 |
Calculation of Filing Fee Table. Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Rockwell Medical, Inc. |
|
| August 14, 2023 |
Execution Version ASSET PURCHASE AGREEMENT BY AND BETWEEN EVOQUA WATER TECHNOLOGIES LLC (“Seller”) AND ROCKWELL MEDICAL, INC. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| August 14, 2023 |
ROCKWELL MEDICAL, INC. AMENDED AND RESTATED 2018 LONG TERM INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On April 13, 2018, the Board initially adopted the Rockwell Medical, Inc. 2018 Long Term Incentive Plan, subject to the approval of shareholders at the Corporation’s 2018 annual meeting of shareholders. The plan was first amended and restated effective May 18, 2020, further amended an |
|
| August 14, 2023 |
ROCKWELL MEDICAL, INC. July 10, 2023 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Rockwell Medical, Inc., a Delaware corporation (the “Company”), is pleased to offer to you the opportunity to exercise all of the Common Stock Purchase Warrant issued to you on June 2, 2022 (with a current exercise price of $1.39 per share), (the |
|
| August 14, 2023 |
Rockwell Medical Announces Second Quarter 2023 Results Rockwell Medical Announces Second Quarter 2023 Results •Net sales for the six months ended June 30, 2023 was $37. |
|
| August 14, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| July 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2023 |
Exhibit 99.1 Rockwell Medical Acquires Hemodialysis Concentrates Business from Evoqua Water Technologies Adds profitable business that generates approximately $18 million in annual revenue and will add over $3.3 million in annual EBITDA for Rockwell Medical. Significantly expands Rockwell Medical's geographic footprint, customer base, and product offerings; Adds fully automated manufacturing know- |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 15, 2023 |
Rockwell Medical, Inc. Corporate Presentation, dated a20230515rmtiinvestorpre |
|
| May 15, 2023 |
Rockwell Medical Announces First Quarter 2023 Results Exhibit 99.1 Rockwell Medical Announces First Quarter 2023 Results •Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022 •Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022 •Continued to reduce expenses and improve earnings per share with focus on driving enhanc |
|
| May 15, 2023 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| April 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2023 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| April 13, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 13, 2023 |
Letter from Marcum, LLP, dated April 13, 2023 a11-890xform8xkattachmen Marcum LLP n 500 W. Monroe Street n Suite 2000 n Chicago, Illinois 60661 n Phone 312.632.5000 n Fax 312.632.5001 n www.marcumllp.com April 13, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Rockwell Medical, Inc. under Item 4.01(a) of its Form 8-K dated April 10, 2023. We agree with the sta |
|
| April 10, 2023 |
Rockwell Medical, Inc. Corporate Presentation, dated a202304rmtiinvestorprese |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 30, 2023 |
Form of Restricted Stock Unit Award Agreement Employee Version (2018 Long Term Incentive Plan). Grantee: Grant Date: Number of Restricted Stock Units: RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”), dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc. |
|
| March 30, 2023 |
DISTRIBUTION TERMINATION AND ACQUISITION AGREEMENT This Distribution Termination and Acquisition Agreement (the “Agreement”) is entered into the date both Parties have signed this agreement, and is between Baxter Healthcare Corporation, a Delaware corporation (“Baxter” or “Distributor”), and Rockwell Medical, Inc. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-236 |
|
| March 30, 2023 |
Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results •Achieved third consecutive quarter of revenue growth with new high of $19. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 30, 2023 |
Form of Restricted Stock Unit Award Agreement Director Version (2018 Long Term Incentive Plan). Grantee: Grant Date: Number of Restricted Stock Units: RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”), dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc. |
|
| February 23, 2023 |
US7743743004 / Rockwell Medical Inc / Richmond Brothers, Inc. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 774374300 (CUSIP Number) DAVID S. RICHMOND RICHMOND BROTHERS, INC. 3568 Wildwood Avenue Jackson, Michigan 49202 (517) 435-4040 (Name, Address |
|
| February 14, 2023 |
US7743743004 / Rockwell Medical Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-rmti123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ROCKWELL MEDICAL, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 774374300 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2023 |
US7743743004 / Rockwell Medical Inc / DAVITA INC. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 774374300 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the |
|
| February 2, 2023 |
Rockwell Medical, Inc. Corporate Presentation, dated February 1, 2023 a202302rmtiinvestorprese |
|
| February 2, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2022 |
Amended and Restated Bylaws (Exhibit 3.1 to the Company’s Form 10-Q filed November 14, 2022). AMENDED AND RESTATED BYLAWS OF ROCKWELL MEDICAL, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as otherwise |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 14, 2022 |
Exhibit 99.1 Rockwell Medical Provides Business Strategy Update and Announces Third Quarter 2022 Financial and Operational Results •Rockwell is restructuring its business in the short-term to drive revenue and expansion opportunities in the growing hemodialysis market and through international pharmaceutical sales •By making this strategic shift, Rockwell expects to achieve profitability in 2024, |
|
| November 14, 2022 |
Grantee: Grant Date: Number of Option Shares: Exercise Price Per Share: $ STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT, dated as of the grant date set forth above (the “Grant Date”), is made by and between Rockwell Medical, Inc. |
|
| November 14, 2022 |
Rockwell Medical, Inc. Short-Term Incentive Plan (Annual Bonus Plan) SECTION 1: Establishment of Plan; Purpose of Plan 1.1. Establishment of Plan. The Company hereby establishes the SHORT-TERM INCENTIVE PLAN (ANNUAL BONUS PLAN) (the “Plan”), for its executive officers, senior corporate and divisional officers and other key employees. The Plan provides for the payment of Incentive Bonuses to Partic |
|
| November 14, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKW |
|
| November 14, 2022 |
by and among the Company, Innovatus Life Sciences Lending Fund I, LP and the lenders party thereto. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 14, 2022 by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), and the Lenders listed on Schedule 1. |
|
| August 16, 2022 |
Rockwell Medical, Inc. Form of Inducement Stock Option Grant and Award Agreement Exhibit 99.2 Employee Grantee: Grant Date: Expiration Date: Number of Option Shares: Exercise Price Per Share: $ INDUCEMENT AWARD STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (the ?Agreement?), dated as of the grant date set forth above (the ?Grant Date?), is made by and between Rockwell Medical, Inc., a Delaware corporation (the ?Company?), and the individual set forth above, who is an empl |
|
| August 16, 2022 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Rockwell Medical, Inc. |
|
| August 16, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 15, 2022 |
Rockwell Medical Announces Second Quarter 2022 Results Exhibit 99.1 Rockwell Medical Announces Second Quarter 2022 Results ?Revenue was $18.7 million for the second quarter 2022, a 16% increase over the first quarter 2022, representing the highest quarterly revenue to-date for Rockwell ?Gross profit was $1.7 million in the second quarter 2022 compared to gross loss of $786,000 in the first quarter 2022 ?Cash used in operating activities was $5.8 milli |
|
| August 15, 2022 |
Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan. ROCKWELL MEDICAL, INC. AMENDED AND RESTATED 2018 LONG TERM INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On April 13, 2018, the Board initially adopted the Rockwell Medical, Inc. 2018 Long Term Incentive Plan, subject to the approval of shareholders at the Corporation's 2018 annual meeting of shareholders. The plan was first amended and restated effective May 18, 2020, further amended an |
|
| August 15, 2022 |
Employment Agreement This Employment Agreement (the ?Agreement?) is made as of June 21, 2022 (the ?Effective Date?), by and between Rockwell Medical, Inc. |
|
| August 15, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| July 26, 2022 |
ROCKWELL MEDICAL, INC. 1,404,956 Shares of Common Stock 424B5 1 tm2220764-4424b5.htm 424B5 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-266135 Prospectus ROCKWELL MEDICAL, INC. 1,404,956 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the “Selling Stockholder”) is offering on a resale basis an aggregate of 1,404,956 shares (the “Shares”) of common stock, par value $0.0001 per s |
|
| July 20, 2022 |
Rockwell Medical, Inc. 30142 S. Wixom Road Wixom, Michigan 48393 (248) 960-9009 July 20, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Joshua Gorsky Re: Rockwell Medical, Inc. Registration Statement on Form S-3 Filed July 14, 2022 File No. 333-266135 Ladies and Gentlemen: In accordance with Rule 461 promulgated under |
|
| July 14, 2022 |
As filed with the Securities and Exchange Commission on July 14, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 14, 2022 Registration No. |
|
| July 14, 2022 |
EX-FILING FEES 4 tm2220764d2ex-filingfees.htm EX-FILING FEES EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Rockwell Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim |
|
| July 7, 2022 |
ROCKWELL MEDICAL, INC. 11,168,887 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-265768? PROSPECTUS ROCKWELL MEDICAL, INC. 11,168,887 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the ?Selling Stockholder?) is offering on a resale basis an aggregate of 11,168,667 shares (the ?Shares?) of common stock, par value $0.0001 per share, of Rockwell Medical, Inc. |
|
| June 30, 2022 |
Rockwell Medical, Inc. 30142 S. Wixom Road Wixom, Michigan 48393 (248) 960-9009 June 30, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Alan Campbell Re: Rockwell Medical, Inc. Registration Statement on Form S-1 Filed June 22, 2022 File No. 333-265768 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated und |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 16)1 Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value 0.0001 per share (Title of Class of Securities) 774374102 (CUSIP Number) DAVID S. RICH |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 22, 2022 |
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer Exhibit 99.1 Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer WIXOM, Mich., June 22, 2022 - Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive |
|
| June 22, 2022 |
EX-FILING FEES 4 tm2218844d2ex-filingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables S-1 (Form Type) Rockwell Medical, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr |
|
| June 22, 2022 |
As filed with the Securities and Exchange Commission on June 22, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 22, 2022 Registration Statement No. |
|
| June 13, 2022 |
Exhibit 99.1 Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation June 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical?s intention to develop FPC for new indications, and maintain concentr |
|
| June 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 2, 2022 |
Form of Pre-Funded Warrant (Exhibit 4.1 to the Company’s Form 8-K filed on June 2, 2022). Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ROCKWELL MEDICAL, INC. Warrant Shares: Issue Date: June 2, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Closing Date ( |
|
| June 2, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 30, 2022, between Rockwell Medical, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| June 2, 2022 |
Form of PIPE Pre-Funded Warrant (Exhibit 4.3 to the Company’s Form 8-K filed on June 2, 2022). Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 2, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of May 30, 2022, between Rockwell Medical, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on the signature pages hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant |
|
| June 2, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of June 2, 2022, between Rockwell Medical, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase A |
|
| June 2, 2022 |
Form of PIPE Warrant (Exhibit 4.2 to the Company’s Form 8-K filed on June 2, 2022). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 1, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-259923? PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2021) ROCKWELL MEDICAL, INC. 844,613 Shares of Common Stock Pre-Funded Warrants to Purchase up to 7,788,480 Shares of Common Stock (and 7,788,480 shares of Common Stock underlying such Pre-Funded Warrants) We are offering 844,613 shares of common stock at a publi |
|
| May 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 20, 2022 |
Exhibit 99.1 Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation May 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical?s intention to develop FPC for new indications, and maintain concentra |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2022 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| May 16, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of April 6, 2022 (the ?Effective Date?) by and among Rockwell Medical, Inc., a Delaware corporation (the ?Company?) and DaVita Inc. (the ?Purchaser?). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 11 hereof. RECITALS WHEREA |
|
| May 16, 2022 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| May 16, 2022 |
Rockwell Medical Provides First Quarter 2022 Financial and Operational Update -First quarter net sales of $16. |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 13, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ROCKWELL MEDICAL, INC. Rockwell Medical, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: 1. The current name of the Corporation is Rockwell Medical, I |
|
| May 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission File |
|
| April 18, 2022 |
RMTI / Rockwell Medical Inc / DAVITA INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Rockwell Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 774374102 (CUSIP Number) April 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to Which |
|
| April 11, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2022 Date of Report (Date of earliest event reported) Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 11, 2022 |
EX-1.1 2 tm2212156d2ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 ROCKWELL MEDICAL, INC. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales Agreement April 8, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Rockwell Medical, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-236 |
|
| April 8, 2022 |
our Definitive Proxy Statement on Schedule 14A filed on April 8, 2022; and TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 8, 2022 |
Exhibit 3.1 ROCKWELL MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES X CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW ROCKWELL MEDICAL, INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does hereby certify that, |
|
| April 8, 2022 |
Description of Securities (Exhibit 4.2 to the Company's Form 10-K filed on April 8, 2022) Exhibit 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our certificate of incorporation, our bylaws and applicable provisi |
|
| April 8, 2022 |
ROCKWELL MEDICAL, INC. Up to $12,200,000 Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-259923? PROSPECTUS SUPPLEMENT (To Prospectus dated October 8, 2021) ROCKWELL MEDICAL, INC. Up to $12,200,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, no par value, offered |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 6, 2022 Date of Report (Date of earliest event reported) Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-13718 (Check One) x Form 10-K ? Form 20-F ?Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| January 5, 2022 |
EX-99.1 2 tm221833d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation January 2022 www.RockwellMed.com ROCKWELL MEDICAL, INC. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT (NASDAQ: RMTI) FORWARD - LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including, but not limited to, Roc |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| December 14, 2021 |
Exhibit 99.1 Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion WIXOM, Mich., December 14, 2021 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around t |
|
| December 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| December 10, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 9, 2021 Date of Report (Date of earliest event reported) Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2021 |
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update - Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion - - Company recent |
|
| November 15, 2021 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| November 15, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKW |
|
| October 6, 2021 |
Rockwell Medical, Inc. 30142 S. Wixom Road Wixom, Michigan 48393 (248) 960-9009 October 6, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Rockwell Medical, Inc. Registration Statement on Form S-3 (File No. 333-259923) To Whom it May Concern: Pursuant to Rule 461 under the Securities Act of 1933, |
|
| September 30, 2021 |
As filed with the Securities and Exchange Commission on September 30, 2021. S-3 1 tm2128563-1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 30, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other juris |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 24, 2021 Date of Report (Date of earliest event reported) Rockwell Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| September 30, 2021 |
Exhibit 4.5 ROCKWELL MEDICAL, Inc. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314(a |
|
| September 30, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of September 24, 2021 by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such capacity, ?Collateral Agent?), and the Lenders list |
|
| August 16, 2021 |
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update -Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic? in Turkey- -Extended multi-year distribution agreement with Nipro Medical for dialysis concentrates in LATAM and the Caribbean- -Q2 2021 conference call and webcast scheduled for today at 4:30 p.m. ET- |
|
| August 16, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 17, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 17, 2021 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| May 17, 2021 |
Rockwell Medical, Inc. Provides First Quarter 2021 Financial and Operational Update -Home Infusion FPC Program expected to initiate Phase 2 trial in second half of 2021- -Company received marketing approval in Canada for Triferic AVNU?- -Conference call and webcast on Monday, May 17th at 4:30 p.m. ET- WIXOM, Mich., May 17, 2021 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmac |
|
| April 30, 2021 |
Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 30, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| March 31, 2021 |
Exhibit 99.1 Rockwell Medical Provides Fourth Quarter and Full Year 2020 Financial and Operational Update - 2020 revenue of $62.2 million- -Ended the year with $58.7 million in cash, cash equivalents and investments – -Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET- WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical comp |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-236 |
|
| March 31, 2021 |
List of Subsidiaries (Company's Form 10-K filed on March 31, 2021). EX-21.1 2 exhibit21-listofsubsidiari.htm EX-21.1 Exhibit 21.1 Subsidiaries of Rockwell Medical, Inc. Rockwell Medical, Inc.’s subsidiaries as of December 31, 2020 is listed below: Subsidiaries Jurisdiction of Organization Rockwell Transportation, Inc. Michigan Rockwell Medical India Private Limited India |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2021 |
CUSIP No: 774374102 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Rockwell Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 774374102 (CUSIP Numb |
|
| January 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2021 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| December 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2020 |
Rockwell Medical, Inc. Provides Third Quarter 2020 Financial and Operational Update -Ended the quarter with $67.3 million in cash, cash equivalents and investments ? -Q3 2020 revenue of $15.3 million- -U.S. commercial launch of Triferic? AVNU expected in Q1 2021- -Poised to enroll first patient in Phase 3 clinical trial of Triferic in China- -Unveiled plans to develop FPC platform in new indicatio |
|
| November 9, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKW |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| November 5, 2020 |
Exhibit 3.1 AMENDED & RESTATED BYLAWS OF ROCKWELL MEDICAL, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as |
|
| October 2, 2020 |
RMTI / Rockwell Medical, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 30, 2020 |
RMTI / Rockwell Medical, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 774374102 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Rockwell Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 774374102 (CUSIP Numbe |
|
| September 29, 2020 |
SC 13D/A 1 sc13da151126500209292020.htm AMENDMENT NO. 15 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 15)1 Rockwell Medical, Inc. (Name of Issuer) Common Stock, no par value per sh |
|
| September 25, 2020 |
Form of Warrant (Exhibit 4.1 to the Company's Form 8-K filed on September 25, 2020). EX-4.1 2 tm2031704d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT Rockwell Medical, Inc. Warrant Shares: Issue Date:, 2020 Initial Exercise Date: , 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| September 25, 2020 |
Form of Pre-Funded Warrant (Exhibit 4.2 to the Company's Form 8-K filed on September 25, 2020). Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT Rockwell Medical, Inc. Warrant Shares: Issue Date:, 2020 Initial Exercise Date: , 2020 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| September 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25 (September 23, 2020) ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorpora |
|
| September 25, 2020 |
Securities Purchase Agreement dated September 23, 2020 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 23, 2020, between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| September 25, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissi |
|
| September 24, 2020 |
fpcnewindicationsopportu NEW INDICATIONS OPPORTUNITIES FOR FERRIC PYROPHOSPHATE CITRATE (FPC) Rockwell Medical, Inc. |
|
| September 17, 2020 |
Exhibit 99.1 Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer WIXOM, Mich., September 15, 2020 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and imp |
|
| September 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissi |
|
| September 17, 2020 |
Russell Skibsted Employment Agreement, dated September 1 Execution Copy Exhibit 10.1 Employment Agreement This Employment Agreement (the “Agreement”) is made as of September , 2020 (the “Effective Date”), by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and Russell L. Skibsted (“Executive”), subject to the terms and conditions defined in this Agreement. Whereas, the Company and Executive desire the Executive be employed by |
|
| September 9, 2020 |
Exhibit 99.1 Rockwell Medical Enters into Exclusive License Agreement with Jeil Pharmaceutical Co., Ltd., for the Rights to Commercialize Triferic® in South Korea -Sizable and growing market opportunity with over 78,000 patients receiving hemodialysis annually- WIXOM, Mich., September 09, 2020 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biophar |
|
| September 9, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL M |
|
| August 10, 2020 |
rmti2020q2earningsslided Q2 2020 Financial Results and Business Update August 10, 2020 1 Call Participants Russell Ellison, M. |
|
| August 10, 2020 |
Exhibit 99.1 Rockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update -Q2 2020 revenue of $15.9 million- -Increase in contracted clinics of 44 percent quarter-over-quarter- -Reached contracted annualized treatment volume for Triferic Dialysate of over 400,000- - $40.0 million in cash, cash equivalents and investments available-for-sale as of June 30, 2020- -Q2 2020 conf |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| July 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission |
|
| July 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 13, 2020 |
rockwellmedicalinvestorp JULY 2020 Forward Looking Language Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical’s intention to commercialize Triferic® Dialysate, and Triferic® AVNU. |
|
| June 29, 2020 |
rockwellmedinvestorprese JUNE/JULY 2020 Forward Looking Language Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell Medical’s intention to commercialize Triferic® Dialysate, and Triferic® AVNU. |
|
| June 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 19, 2020 |
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK Exhibit 99.1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE ROCKWELL MEDICAL, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No. 1:19-cv-02373-ARR-RER (Consolidated with Case No. 1:19-cv-02774-ARR-RER) This Document Relates To: ALL ACTIONS. Honorable Allyne R. Ross NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL PERSONS OR ENTITIES WHO CURRENTLY HOLD SHAR |
|
| June 19, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 2, 2020 |
File No. 333- As filed with the Securities and Exchange Commission on June 2, 2020. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ROCKWELL MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 38-3317208 (I.R.S. Employer I |
|
| May 21, 2020 |
Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan Exhibit 10.1 ROCKWELL MEDICAL, INC. AMENDED AND RESTATED 2018 LONG TERM INCENTIVE PLAN I. GENERAL PROVISIONS 1.1 Establishment. On April 13, 2018, the Board, adopted the Plan, subject to the approval of shareholders at the Corporation's 2018 annual meeting of shareholders. 1.2 Purpose. The purpose of the Plan is to (a) promote the best interests of the Corporation and its shareholders by encouragi |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 11, 2020 |
United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL |
|
| May 11, 2020 |
Exhibit 99.1 Rockwell Medical, Inc. Provides First Quarter 2020 Financial and Operational Update and Top-line Real-World Triferic Data -Q1 2020 revenue of $15.9 million- -Received FDA Approval of Triferic® AVNUTM- -Significant expansion of Triferic (ferric pyrophosphate citrate) Dialysate Evaluation Programs during Q1 2020- -Retrospective real-world analysis over 18 months shows reduction in ESA a |
|
| May 11, 2020 |
Life Sciences Lending Fund I, LP and the lenders party thereto (Exhibit 10.1 to the Company’s [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 20, 2020 |
Exhibit 99.1 Rockwell Medical, Inc. Appoints Russell H. Ellison, M.D., M.Sc., as President and Chief Executive Officer -Company to Host Q1 2020 Earnings and Corporate Update Call and Webcast on May 11, 2020, at 4:30 p.m. ET- WIXOM, Mich., April 20, 2020 (GLOBE NEWSWIRE) - Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transform |
|
| April 20, 2020 |
Russell Ellison Employment Agreement, dated April 17, 2020 Exhibit 10.1 - Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of April 17, 2020 (the “Effective Date”), by and between Rockwell Medical, Inc., a Delaware corporation (the “Company”), and Russell H. Ellison MD (“Executive”), subject to the terms and conditions defined in this Agreement. WHEREAS, the Company and Executive desire that Executive be employ |
|
| April 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| April 20, 2020 |
Our Definitive Proxy Statement filed with the SEC on April 20, 2020; DEF 14A 1 rmti-20200518xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 27, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Rockwell Medical, Inc. Receives FDA Approval for Triferic® AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients – Enhances Triferic platform by providing patients with greater access to Rockwell Medical’s innovative therapeutic by expanding administration options fo |
|
| March 27, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2020 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 000-23661 38-3317208 (State or other jurisdiction of incorporation) (Commission F |
|
| March 20, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Rockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC - First $22.5 million tranche funded at closing - WIXOM, Mich., March 17, 2020 – Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for pa |
